lol, you're a funny guy, CT. You make this post and warn me via PM that you'll ban me if I say anything else. You're turning a discussion board into an army base. You weren't civil about this whole discusion to begin with. Who gave you the right to insult people, CT? Are you special? Where's the studies to prove that var always shuts you down? You conviniently backed down from that argument and decided to butt in on my opinion on Prami.
My "Warning" said that your acting like an ass and that if you don't like it, leave. 99% of people would have banned you from the start. Tell the truth and how it was really stated. I also never stated that I would ban you if you said anything else, that's just not true and you know it.
Here are the two studies I am referring to:
Efficacy, safety and dose-response of pramipexole: randomized trial.
Inoue Y,
Kuroda K,
Hirata K,
Uchimura N,
Kagimura T,
Shimizu T.
Japan Somnology Center, Neuropsychiatric Research Institute, Tokyo, Japan.
inoue@somnology.com
Abstract
AIMS: To assess the safety and efficacy of pramipexole and to investigate factors predictive of early treatment response.
METHODS: Patients with primary RLS and the International Restless Legs Syndrome Study Group rating scale (IRLS) total score of >15 were randomized to receive pramipexole 0.25, 0.5 or 0.75 mg/day for 6 weeks.
RESULTS: A total of 154 patients were recruited. Following treatment, the mean adjusted change in IRLS score in the 0.25, 0.5 and 0.75 mg/day groups was -12.3, -12.5 and -11.8, respectively. The proportion of IRLS responders at week 2, when all patients were receiving pramipexole at a dose of 0.25 mg/day, was 34.0-37.7%.
At 6 weeks, when the patients were on 0.25, 0.5 or 0.75 mg/day, IRLS responders defined as those having a ≥50% reduction in IRLS score accounted for 60.4, 58.5 and 49.1%, respectively. Older age above the median value (≥55 years) and low IRLS score at baseline (<21.5 points) were significantly associated with early response to low-dose pramipexole therapy. The type and frequency of adverse events were consistent with the known safety profile for dopamine agonists in RLS.
CONCLUSIONS: Pramipexole at 0.25-0.75 mg/day is efficacious, safe and well tolerated.
The effects of oxandrolone on the growth hormone and gonadal axes.
Malhotra A, Poon E, Tse WY, Pringle PJ, Hindmarsh PC, Brook CG.
Endocrine Unit, Middlesex Hospital, London, UK.
Abstract
OBJECTIVE: We studied the effects of oxandrolone on serum concentrations of LH, FSH, testosterone, GH, SHBG, DHEAS, IGF-I and insulin in men with constitutional delay of growth.
DESIGN: Ten men with constitutional delay of growth, mean age 18.8 years (range 17.4-22.5) were studied. Twenty-four-hour serum concentration profiles of GH, LH and FSH were constructed by drawing blood samples at 20-minute intervals.
Three study occasions over a period of 6 months were chosen to assess hormone concentrations before, during and 6 weeks after a 3-month course of oxandrolone (2.5 mg once daily) therapy.
RESULTS: Growth velocity increased during oxandrolone treatment and stayed higher after therapy (pre 3.9 +/- 0.5; on 6.3 +/- 0.8; post 6.4 +/- 0.9 cm/year (mean +/- SEM) two way ANOVA, F = 5.3, P = 0.02).
Oxandrolone had androgenic effects, suppressing mean serum LH concentrations from 1.7 +/- 0.3 to 1.1 +/- 0.2 U/I and serum testosterone concentrations from 1.9 +/- 0.6 to 0.8 +/- 0.1 nmol/l. SHBG concentrations were also reduced from 130.9 +/- 14.6 to 30.7 +/- 7.3 nmol/l. Serum GH concentration fell slightly from 5.9 +/- 0.6 to 4.8 +/- 0.5 mU/l.
After cessation of treatment, there was a significant 'rebound' in mean 24-hour serum LH (2.6 U/l +/- 0.4) and testosterone concentrations (3.2 +/- 0.9 nmol/l) but no change in serum GH concentrations. SHBG values also rose but not to the same extent as those observed before therapy (82.0 +/- 8.4 nmol/l). There were no statistically significant differences in serum concentrations of FSH, DHEAS, IGF-I and insulin over the study period. In a stepwise multiple regression analysis of factors that might influence the growth rate observed, the 24-hour mean serum testosterone concentration and the treatment (on or off) with oxandrolone were the main influences. The relationship was described by the equation Height velocity = 0.69 (24-hour mean serum testosterone concentration)+1.70 (treatment regimen)+3.37 (adjusted R2 = 0.35, F = 8.39, P = 0.001).
CONCLUSIONS: Oxandrolone has an androgenic action as shown by decreased changes in serum LH, FSH, testosterone and SHBG concentrations. No effect of oxandrolone on the GH axis was documented. We suggest that the growth promoting effects of oxandrolone are related in part to the mild androgenic effects of the steroid and the growth acceleration
following oxandrolone withdrawal reflects increasing total serum testosterone concentrations and decreasing levels of SHBG and progress.
Please feel free to post your studies or tell me that these are indeed wrong.
